Keynote Speakers

Peter H. Seeberger

Max Planck Institute of Colloids and Iterfaces, Potsdam, Germany
Freie Universität, Berlin, Germany

Vaccines, antibody therapies and diagnostics based on synthetic carbohydrates

Stephan Bachmann

F. Hoffmann-La Roche Ltd.,
Basel, Switzerland

Catalytic applications in the scale-up of API processes

Frank Wagner

Charité, Berlin, Germany

Clinical trial design: A paradigm shift in early clinical trials

Invited Speakers

Daniela Angst

Novartis

Discovery of remibrutinib, a covalent BTK inhibitor

Roy Bar-Ziv

Weizmann Institute of Science, Rehovot, Israel

Cell-free synthetic biology

Martina Benešová

German Cancer Research Center

Molecular Biology of Systemic Radiotherapy

Andrea Brancale

UCT Prague, ČR

Will be announced

Oliviana Calin-Eller

E. Blum & Co. AG, Zurich, Switzerland

Patents in Medicinal Chemistry/Life Science

Richard Clarkson

Cardiff University, UK

Assessing efficacy of new anticancer treatments at pre-clinical level

Camille Correia

Merck Electronics KGaA, Darmstadt, Germany

Modular continuous automation for laboratories and production

Deborah Fass

Weizmann Institute of Science, Rehovot, Israel

Mucins and fibrosis

Paulina Kaplonek

Moderna, USA

Identifying the correlates of immunity for better vaccine design

Valery Khrizanovsky

Weizmann Institute of Science, Rehovot, Israel

Senescence

Jan Konvalinka

IOCB Prague, ČR

The elusive mechanisms of unexpected regulators of inflammatory and growth factor signalling

Sima Lev

Weizmann Institute of Science, Rehovot, Israel

Breast cancer

David Margulies

Weizmann Institute of Science, Rehovot, Israel

Bioorthogonal chemistry

Petra Ménová

UCT Prague, ČR

Drug discovery and development

Johan Neyts

KU Leuven, Belgium

Discovery and development of antiviral drugs

Jitka Palich Fučíková

Sotio Biotech Department of Immunology, 2nd Medical school, Charles University

The immune contexture in cancer prognosis and response to immunotherapy

Christoph Rademacher

University of Vienna

Molecular drug targeting

Pavlína Řezáčová

IOCB Prague, ČR

Structure-assisted design of enzyme inhibitors

Jitka Riedl

Bicycle Therapeutics, Cambridge, UK

Bicycle peptides as precision-guided cancer therapeutics

Menachem Rubinstein

Weizmann Institute of Science, Rehovot, Israel

Cytokines in disease

Gideon Schreiber

Weizmann Institute of Science, Rehovot, Israel

Protein interactions

Marek Šťastný

Bristol Myers Scribb ČR

PDL-1

Kvido Stříšovský

IOCB Prague, ČR

Chemical-biology tools in drug development

Michal Tichý

IOCB Prague, ČR

Kinase Inhibitors: From insoluble and promiscuous hit to drug candidate

Igor Ulitsky

Weizmann Institute of Science, Rehovot, Israel

RNA in disease

Kateřina Vávrová

Faculty of Pharmacy Hradec Kralove, Charles University, ČR

Transdermal drug administration

Milan Vrábel

IOCB Prague, ČR

Development and application of bioorthogonal reactions in medicine and beyond

Stella Vukelic

AbbVie

Will be announced

Yosef Yarden

Weizmann Institute of Science, Rehovot, Israel

Signalling in cancer